Tumor reactive plasma cells (TRPC’s) have been revealed to be correlated with prolonged survival in patients with different cancers. Nevertheless, differently from tumour-specific antigen (TSA) - stimulated T cells which possess accurate actions against tumors, plasma cells (PCs) have requirement of TSA for procuring particular reactions. Thereby the lookout for TSA appropriate for B cell recalling is mandatory at earliest. Here we evaluate the working of TRPC’. Additionally, we investigate the posit of screening for neoantigen reactive plasma cells getting motivated from T cells screening methodologies. Whereas hurdles are present, these epitopes anticipation and efficacious screening, generating innovative modalities, might cause invention of considerably specialized adoptive cell therapy (ACT). Previously we had detailed different gynaecological cancers, like high grade serous ovarian cancers (HGSOC), breast cancer (BC), HCC. Additionally, we reviewed mechanistic modes of various cancers including targeting PI3K/PTEN/AKT signaling pathways in treating germ cell tumors, MAPK/ERK and Hippo/MST signaling for cancers targeting programmed death 1 (PD1)/programmed death ligand 1(PDL1) pathways in ovarian cancers and mucin by tecemotide therapy for non small lung cancer (NSCLC). Recently we updated role of immunometabolism in cancer. Despite availability of considerably good publications regarding tumor infiltrating B cells, here we concentrated on working of TRPC’s. Particularly our emphasis is on maximum recent scientific studies adding to working of TRPC’s, recent advancements made in enhancement of antigens which possess the capacity of greater induction of plasma cells and lastly posit an approach for screening tumour-specific antigen (TSA) - reactive plasma cells. Thereby TRPC’s are coming up as robust actors in cancer immunotherapy. Their capacity to generate antibodies against a range of antigens particularly neoantigens opens innovative arenas for individualized treatment. Getting over these hurdles in epitopes anticipation and screening might be key in garnering the total probability of getting advantages for cancer cases.

Keywords: Plasma Cells; Tumor Infiltrating B Cells; Tumour-Specific Antigen; Tumor Reactive Antibodies

References

1. Wouters MA and Nelson BH. “Prognotic significance of tumor infiltrating B cells and plasma cells in human cancer”. Clinical Cancer Research24 (2018): 6125-6135.
2. Sharonov GV., et al. “B cells, plasma cells and antibody repertoires in the tumor microenvironment”. Nature Reviews Immunology5 (2020): 294-307.
3. Li K., et al. “Oral cancer associated tertiary lymphoid structures: gene expression and prognostic value”. Clinical and Experimental Immunology2 (2020): 172-181.
4. Wieland A., et al. “Defining HPV specific cell responses in head and neck cancer”. Nature7875 (2021): 274-278.
5. Mazor RD., et al. “Tumor reactive antibodiesevolve from non binding and auto reactive precursors”. Cells77 (2022): 1208-1222.e21.
6. Paston SJ., et al. “Cancer vaccines, adjuvants and delivery systems”. Frontiers in Immunology 12 (2021): 627932.
7. Kulvinder Kochar Kaur., et al. “Advances in the Therapy of Advanced Ovarian Cancer-Special Emphasis on the PD1/PDL1 Pathway”. Current Trends in Biomedical Engineering and Bioscience2 (2016): CTBEB.MS.ID.555557.
8. Kulvinder Kochar Kaur., et al. “Tacemotide-an immunotherapy for advanced cancers expressing mucin-is it reality for future elimination of advanced cancers - a Review”. (2016).
9. Kulvinder Kochar Kaur., et al. “Can Using Plant Derived Agents for Cancer Like Geniposide and Genipin Change the Future of Cancer chemotherapy – A Short Communication". Acta Scientific Nutritional Health9 (2019): 161-164.
10. Kulvinder Kochar Kaur., et al. “Alteration in Natural Killer (NK) cell Function in Obesity-correlating with comorbidities development like cancer and type 2diabetes-A minireview”. J Endocrinol 3.2 (2019): 000140. DOI: 10.23880/oaje-16000140
11. Kulvinder Kochar Kaur., et al. “Importance of controlling obesity and associated immune response changes in prevention and treatment of cancer– with plant therapies of help”. Advances in Obesity Weight Management and Control 4 (2019): 114-116.
12. Kulvinder Kochar Kaur., et al. “Role of Polyphenols like Resveratrol in Cancer Prevention and Treatment-Especially in Combination with Other Polyphenols Like Quercetin-Detailed Mode of Action and Future Perspectives-A Systematic Review”. Acta Scientific Cancer Biology7 (2020): 13-20.
13. Kulvinder Kochar Kaur., et al. “Escalation of Efficacy and Prevention of Chemoresistance in Various Cancer Therapies by the Utilization of Targeting the Crosstalk Amongst MAPK/ERK Along with Hippo/MST Signaling - A Comprehensive Review". Acta Scientific Cancer Biology9 (2021): 37-47.
14. Kulvinder Kochar Kaur., et al. “The mechanistic modes of Targeting immunometabolism in cancer :An innovative strategy-a narrative review”. (2024).
15. Garand S., et al. “Tumor infiltrating B cells signal functional humoral immune responses in breast cancer”. JCI Insight18 (2019): e129641.
16. Helmink BA., et al. “B cells and tertiary lymphoid structures promote immunotherapy response”. Nature7791 (2020): 549-555.
17. Dang VD., et al. “From the regulatory functions of B cells to the identification of cytokines producing plasma cell subsets”. Current Opinion on Immunology 28 (2014): 77-83.
18. Saures-Fridman C., et al. “Tertiary lymphoid structures in cancers: Prognotic value, regulation and manipulation for therapeutic intervention”. Frontiers in Immunology 7 (2016): 407.
19. Patil NS., et al. “Intra tumor plasma cells predict outcomes toPd-l1 blockade in non small lung cancer”. Cancer Cell3 (2022): 289-300.e4
20. Stockert E., et al. “A survey of the humoral immune response of cancer patients to a panel of human tumor antigens”. Journal of Experimental Medicine 8 (1998): 1349-1354.
21. MacDonald IK., et al. “Autoantibodies: opportunities for early cancer detection”. Trends Cancer3 (2017): 198-213.
22. , et al. “T cell invigoration to tumor burden ratio associated with antiPd-1 response”. Nature 545.7652 (2017): 60-65.
23. , et al. “High densities of tumor associated plasma cells predict improved prognosis in triple negative breast cancer”. Frontiers in Immunology 9 (2018): 1209.
24. , et al. “Crosstalk between myeloid and B cells shape the distinct microenvironments of primary and secondary liver cancer”. Cancer Research 83.21 (2023): 3544-61.
25. Tan TT and C LM. “Humoral immunity, inflammation and cancer”. Current Opinion on Immunology2 (2007): 209-216.
26. Aziz M., et al. “Role of circulating immune complexes in prognostic evaluation and management of genitourinary cancer patients”. Indian Journal of Cancer3 (1997): 111-120.
27. Yuen GJ., et al. “B lymphocytes and cancer: love hate relationship”. Trends Cancer12 (2016): 747-757.
28. Soussi T. “P53 antibodies in the sera of patients with various types of cancer: a review”. Cancer Research7 (2000): 1777-1788.
29. Zalcman G., et al. “Monitoring of P53 antibodies in lung cancer duringtherapy: relationship to response to treatment”. Clinical Cancer Research6 (1998): 1359-1366.
30. Berqvist M., et al. “The role of Circulating P53 antibodies in patients with advanced non small lung cancer and their correlation to Clinical parameters and survival”. BMC Cancer 4 (2004): 66.
31. Kumar S., et al. “Prognotic implications of Circulating anti p53 antibodies in lung cancer :a review”. European Journal of Cancer Care (Eng’)3 (2009): 248-254.
32. Chen P., et al. “Tumor reactive plasma cells in antitumor immunity: current insights and future prospects”. Immunotherapy Advances 4 (2024): itae003.
33. Liu W., et al. “Peptide based therapeutic cancer vaccines: current trends in clinical applications”. Cell Prolify 5 (2021): e13025.
34. , et al. “Towards personalized tumor specific therapeutic vaccines for cancer”. Nature Reviews Immunology 18.3 (2018): 168-182.
35. , et al. “Cysteine carboxyethylation generates neoantigens to induceHla restricted autoimmunity”. Science 379.6637 (2023): eabg2482.
36. , et al. “Non viral oncogenic antigens and the inflammatory signals driving earlycancer development as targets for cancer prevention”. Clinical Cancer Research 21.7 (2015): 1549-1557.
37. , et al. “Personalized cancer neoantigens vaccines come of age”. Theranostics 8.15 (2018): 4238-4246.
38. , et al. “Personalized RNA neoantigens vaccines stimulate T cells in pancreatic cancers”. Nature 618.7963 (2023): 144-150.
39. Blass E and Ott PA. “Advances in the development of Personalized neoantigen based vaccines therapeutic cancer vaccines”. Nature Reviews Clinical Oncology4 (2021): 215-229.
40. , et al. “Neoantigen driven B cell andCd4 T follicular helper cells collaboration promotes antitumor Cd8 T cell response”. Cell 184.25 (2021): 6101-6018.
41. Kumar A., et al. “Cell therapy with TIL’s training and taming T cells to fight cancer”. Frontiers in Immunology 12 (2021): 690499.
42. Liu Z., et al. “Detecting tumor antigen specific T cells via interaction- dependent fucosyl biotinylation”. Cell 4 (2020): 1117-1133.e9.
43. Hanada K., et al. “A phenotypic signature that identifies neoantigen reactive T cells in fresh human lung cancers”. Cancer Cell5 (2022): 479-93.e6.
44. Lin WP., et al. “T cell exhaustion initiates tertiary lymphoid structures and turbocharges cancer immunity cycles”. EBioMedicine 104 (2024): 105154.
45. Mandal G and Pradhan S. “B cell responses and antibody based therapeutic perspectives in human cancers”. Cancer Report 7 (2024): e2056.

Citation

Citation: Kulvinder Kochar Kaur and Gautam Allahbadia. “The Emerging Innovative Modalities in Antitumor Immunity Utilizing Tumor Reactive Plasma Cells for Escalating Cancer Survival – A Mini Narrative Review”.Acta Scientific Cancer Biology 8.7 (2024): 03-15.

Copyright

Copyright: © 2024 Kulvinder Kochar Kaur and Gautam Allahbadia. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.